InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,186.98
(
0.12%
)
US TECH 100
17,649.59
(
0.22%
)
Dow Jones
38,870.22
(
0.05%
)
Brent Oil
83.33
(
-0.18%
)
Bitcoin
63,427.97
(
0.41%
)
Post# of 251744
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

caravon

Send PM Follow Ignore
Followers 13
Posts 1058
Boards Moderated 0
Alias Born 02/21/2007

caravon

Re: pollyvonwog post# 190470

Sunday, 04/26/2015 12:36:50 PM

Sunday, April 26, 2015 12:36:50 PM

Post# of 251744
Purpose (FROM ABBVIE’S PHASE 3B RUBY-I STUDY)

This open-label study will evaluate safety, pharmacokinetics and efficacy of a 12 or 24 week regimen of ombitasvir/ABT-450/ritonavir and dasabuvir with or without ribavirin in HCV-genotype 1-infected subjects with an Estimated Glomerular Filtration Rate (eGFR) <30, including those on hemodialysis.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up